What if David and Goliath teamed up instead?

The Flash Report

25 Mar 2026 — 1 min read

That’s what’s currently playing out in the foodservice industry, where industry goliaths Sodexo, Aramark, and Compass Group all partnered with foodtech startup Automated Retail Technologies.

Why did they choose ART? With more than 150,000 venues managed by that trio alone, staffing overnight operations is costly and complicated. With ART’s Just Baked™ automated robotic kiosks, serving peoples’ favorite meals 24/7 is affordable and easy.

It’s not just foodservice providers, either. Restaurant partners like White Castle deploy branded kiosks to serve new markets at .001% the cost of new brick-and-mortar locations. Brands like Nestlé and Wow Bao partner to keep items stocked and ready.

But that’s only scratching the surface of why ART is gaining traction so quickly.

Automation: Just Baked™ kiosks eliminate the need for kitchens, overnight staff, or delivery logistics — serving hot meals in minutes while solving one of foodservice’s most persistent operational challenges.
Distribution: Through partnerships with the world’s largest foodservice operators and global food manufacturers, ART is embedding its platform into airports, hospitals, universities, corporate campuses, and other high-traffic venues.
Opportunity: Until March 25, everyday investors have the chance to maximize their stake in ART’s growth with up to 15% bonus stock, just as automated foodservice begins scaling nationwide.

And ART’s 800 units deployed currently only scratches the surface of their growth plans. They have 400 more units ready for immediate deployment, 340,000+ additional targeted locations, and a leadership team that knows exactly what it takes to scale. In other words, ART is perfectly positioned.

Now, you can share in this industry-altering as an early-stage ART investor before they scale to 340,000+ targeted locations. Invest before March 25 to claim your limited-time bonus.

This is a paid advertisement for Automated Retail Technologies Regulation CF offering. Please read the offering circular at https://invest.automatedrt.com/

The Biggest Unsolved Problem in Medicine?

Today, over half a billion people battle osteoarthritis. Each year, they spend $240B trying to halt the destruction of joint cartilage. But no cure exists on the market. Not for lack of trying, either. Big Pharma’s spent billions failing. Thankfully, Cytonics may have cracked the code. They discovered the

The Key to This $500B Market Is in Your Bloodstream

Every year, $240B is spent on treating the symptoms of osteoarthritis, a disease that leads to joint degradation and, eventually, immobility. With 500M people afflicted, its total addressable market is worth over $500B. But not a single therapy has been able to actually stop it. The answer, it turns out,

Superhuman' Pre-IPO Stock Trading Under $1

Have you heard about this sub $1 Pre-IPO company that is making people "Superhumans"? It's all thanks to their new product called Visor. And it's very similar to Jarvis from the movie Iron Man. Investors are calling this a 'massive breakthrough'. But

This Pre-IPO Stock is Up 4,000% Already

What do you do after 4,000% growth? If you’re Immersed, you build the future. How do you follow 4,000% valuation growth? By preparing for what’s next. That’s what Immersed did, reserving the Nasdaq ticker $IMRS. But the real opportunity for investors is now, before public

Read more

The Biggest Unsolved Problem in Medicine?

The Key to This $500B Market Is in Your Bloodstream

Superhuman' Pre-IPO Stock Trading Under $1

This Pre-IPO Stock is Up 4,000% Already